The project is focused on the elucidation of alterations in signaling pathways leading to survival advantage and resistance to apoptosis in leukemic blast and develops innovative therapeutic approaches, with a focus on CDK7 inhibition and modulating redox homeostasis. Further, using in vitro, ex vivo and in vivo models of AML, we seeks to identify critical targets associated with Venetoclax/Cytarabine resistance and incorporate the novel targets in treatment regime to overcome the resistance.